MiMedx Group, Inc (NASDAQ:MDXG) Receives Average Recommendation of “Moderate Buy” from Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $9.60.

MDXG has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Wall Street Zen cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Mizuho dropped their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Citizens Jmp initiated coverage on MiMedx Group in a research report on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 target price for the company. Finally, Cantor Fitzgerald decreased their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. World Investment Advisors purchased a new stake in shares of MiMedx Group during the fourth quarter valued at $173,000. Virtu Financial LLC acquired a new stake in MiMedx Group during the 4th quarter worth about $78,000. Invesco Ltd. raised its holdings in MiMedx Group by 5.9% during the 4th quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock worth $574,000 after buying an additional 4,708 shares during the period. Corient Private Wealth LLC lifted its stake in MiMedx Group by 26.0% during the fourth quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock valued at $316,000 after buying an additional 9,614 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its stake in MiMedx Group by 33.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock valued at $141,000 after buying an additional 5,236 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $4.17 on Friday. The firm’s 50 day moving average is $5.07 and its two-hundred day moving average is $6.32. MiMedx Group has a 52 week low of $4.11 and a 52 week high of $8.13. The firm has a market capitalization of $619.54 million, a P/E ratio of 13.03 and a beta of 1.60. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The company had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million. Analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.